Back to Results
First PageMeta Content
Eribulin / Eisai / Health / Breast cancer / National Health Service / National Institute for Health and Clinical Excellence / Medicine / Ribbon symbolism / Oncology


January 13, 2015 Eisai Co., Ltd. STATEMENT REGARDING NHS ENGLAND’S REASSESSMENT OF HALAVEN® FOR THE CANCER DRUGS FUND Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that, in
Add to Reading List

Document Date: 2015-01-13 01:46:50

Open Document

File Size: 14,95 KB

Share Result on Facebook

City

Tokyo / /

Company

Eisai Co. Ltd. / /

Country

United Kingdom / /

Facility

National Institute / /

IndustryTerm

breast cancer treatment / /

MedicalCondition

metastatic breast cancer / cancer / metatstatic breast cancer / innovative in-house developed breast cancer / advanced breast cancer / breast cancer / /

MedicalTreatment

chemotherapy / /

Organization

Cancer Drugs Fund / National Institute for Health and Clinical Excellence / NHS / National Health Service / /

Position

CEO / /

Technology

chemotherapy / /

SocialTag